期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

弥漫性大B细胞淋巴瘤预后因素分析及不同治疗方案对患者生存的影响 被引量：3

原文传递
导出
摘要 弥漫性大B细胞淋巴瘤（DLBCL）是非霍奇金淋巴瘤（NHL）中发病最多的亚型，占非霍奇金淋巴瘤的30％～40％。为进一步确定弥漫性大B细胞淋巴瘤预后因素及不同化疗方案对患者预后的影响，我们回顾性分析了143例DLBCL患者的临床资料，现报告如下。
作者 余延芳 岑溪南 任汉云 王颖 邱志祥 王文生 欧晋平 许蔚林 王茫桔 李渊 董玉君 王莉红 尹明 孙玉华
机构地区 北京大学第一医院血液科
出处 《中华血液学杂志》 CAS CSCD 北大核心 2009年第6期419-421,共3页 Chinese Journal of Hematology
关键词 弥漫性大B细胞淋巴瘤 预后因素分析 治疗方案 非霍奇金淋巴瘤 DLBCL 化疗方案 临床资料
分类号 R686 [医药卫生—骨科学]
  • 相关文献

参考文献7

  • 1Alizadeh AA,Eisen MB,Dais RE,et al.Distinet types of diffuse large B-cell lymphoma identified by gene expression profiling.Nature,2000,403:503-511.
  • 2Jaffe ES,Harris NL,Stein H,et al,WHO Classification of Tumors.Pathology&Genetics of Tumors of Haematopoietic and Lymphoid Tissues.Lyon:International Agency for Research on Cancer(IARC) Press,2001:171-180.
  • 3杨渤彦,勇威本,朱军,郑文,张运涛,王小沛,孟松娘.弥漫性大B细胞淋巴瘤的临床特征及预后影响因素分析[J].中华肿瘤杂志,2005,27(3):174-176. 被引量：37
  • 4Shipp MA,Harrington DP.A predictive model for aggressive non-Hodgkin's lymphoma.The International Non-Hodgkin's Lymphoma Progrestic Factors Project.N Engl J Med,1993,329:987-994.
  • 5Pfreundschuh M,Trumper L,Kloess M,et al.Two weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good prognosis (normal LDH) aggressive lymphomas:results of the NHL-B1 trial of the DSHHNHL.Blood,2004,104:626-633.
  • 6Coiffier B,Lepage E,Briere J,et al.CHOP chemotherapy plus rituximab compared with CHOP alone in chiefly patients with diffuse large B-cell lymphoma.N Engl J Med,2002,346:235-242.
  • 7Milpied N,Deconinck E,Gaillard F,et al.Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.N Engl J Med,2004,350:1287-1295.

二级参考文献10

  • 1Colomo L, Lopez-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotying in patients with diffuse large B-cell lymphoma. Blood,2003,101: 78-84.
  • 2Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med,2002, 346:235-242.
  • 3Barrans SL, Carter Ⅰ, Owen RG, et al. Germinal center phenotype and expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood,2002,99:1136-1143.
  • 4Koniaris LG, Drugas G, Katzman P J, et al. Management of gastrointestinal lymphoma. J Am Coll Surg,2003,197:127-141.
  • 5Ibrabin EM, Ezzat AA, EI-Weshi AN, et al. Primary intestinal diffuse large B-cell non-Hodgkin's lymphoma: clinical features, management,and progrosis of 66 patients. Ann Oncol,2001,12:53-58.
  • 6Michael MB, Christensen BE, Petersan NT, et al. Prognosis of localized diffuse large B-cell lymphoma in younger patients. Cancer, 2003, 98:516-521.
  • 7Wilder KB, Rodriguez MA, Medeiros LJ, et al. International prognostic index-based outcomes for diffuse large B-cell lymphomas. Cancer,2002,94: 3083-3088.
  • 8Harris NL, Jaffe ES, Diebold J, et al. World-Health Organization classification of neoplastic disease of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting. J Clin Oncol,1999,17: 3835-3849.
  • 9Harris NL, Jaffe ES, Stein H, et al. A revised Europenn-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood, 1994, 84: 1361-1392.
  • 10Diebold J, Anderson JR, Armitage JO, et al. Diffuse large B-cell lymphoma: a clinicopathologic analysis of 444 cases classified according to the updated Kiel classification. Leuk Lymphoma, 2002,43:97-104.

共引文献36

同被引文献52

  • 1Pfreundsehuh M, Trtlmper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-eell lymphoma: a randomised controlled trial by the Mab Thera International Trial (MINT) Group. Lancet Oneol, 2006, 7: 379- 391.
  • 2Pfreundschuh M, Schubert J, Ziepert M, et ah Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol, 2008, 9: 105- 116.
  • 3Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Grouped' Etudes des Lymphomes de l'Aduhe. Blood, 2010, 116 : 2040-2045.
  • 4Chang CC, Cho SF, Chen YW, et al. SUV on dual- phase FDG PET/CT correlates with Ki-67 proliferation index in patients with newly diagnosed non-Hodgkin lymphoma. Clin Nucl Med, 2012, 37 : e189-e195.
  • 5National Comprehensive Cancer Network [ EB/OL ~. [ 2012-02- 231. http ://www. nccn. org/index, asp.
  • 6Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol, 2007, 25:579- 586.
  • 7Chihara D, Oki Y, Onoda H, et al. High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma. Int J Hematol, 2011,93: 502-508.
  • 8Papajlk T, Mysliveffek M, Sedova Z, et al. Standardised uptake value of ^18F-FDG on staging PET/CT in newly diagnosed patients with different subtypes of non-Hodgkin's lymphoma. Eur J Hematol, 2011, 86: 32-37.
  • 9Itti E, Lin C, Dupuis J, et al. Prognostic value of interim ^18F- FDG PET in patients with diffuse large B-cell lymphoma: SUV- based assessment at 4 cycles of chemotherapy. J Nucl Med, 2009, 50 : 527-533.
  • 10Casasnovas RO, Meignan M, Berriolo-Riedinger A, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood, 2011, 118: 37-43.

引证文献3

二级引证文献17

中华血液学杂志
2009年 第6期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部